Evidence map›Paper›PMID 28294177›Full record

ArticleScientific reports2017

Rational Design of Protein C Activators.

Sergio Barranco-Medina, Mary Murphy, Leslie Pelc, Zhiwei Chen, Enrico Di Cera, Nicola Pozzi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. The Prothrombin-Prothrombinase Interaction.Sub-cellular biochemistry · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sergio Barranco-MedinaEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104 USA.
Mary MurphyEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104 USA.
Leslie PelcEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104 USA.
Zhiwei ChenEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104 USA.
Enrico Di CeraEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104 USA.
Nicola PozziEdward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO 63104 USA.
Saint Louis University · ESSaint Louis University · US

Funding

STUDIES ON THROMBIN ALLOSTERYR01HL049413 · NHLBI · WASHINGTON UNIVERSITY · PI Enrico Di Cera · 2000 to 2026
$9.6M
Translational Research Skills Development CoreU54HL112303 · NHLBI · WASHINGTON UNIVERSITY · PI SADLER, J EVAN · 2012 to 2016
$8.8M
Studies on the anticoagulant properties of thrombinR01HL073813 · NHLBI · WASHINGTON UNIVERSITY · PI DI CERA, ENRICO · 2003 to 2015
$5.3M
BIOPHYSICAL STUDIES OF THROMBINR29HL049413 · NHLBI · WASHINGTON UNIVERSITY · PI DI CERA, ENRICO · 1995 to 1999
–
American Heart Association-American Stroke Association 15SDG25550094NHLBI NIH HHS R01 HL049413NHLBI NIH HHS R01 HL073813NHLBI NIH HHS R29 HL049413NHLBI NIH HHS U54 HL112303
6 · The paper itself

Abstract

In addition to its procoagulant and proinflammatory functions mediated by cleavage of fibrinogen and PAR1, the trypsin-like protease thrombin activates the anticoagulant protein C in a reaction that requires the cofactor thrombomodulin and the endothelial protein C receptor. Once in the circulation, activated protein C functions as an anticoagulant, anti-inflammatory and regenerative factor. Hence, availability of a protein C activator would afford a therapeutic for patients suffering from thrombotic disorders and a diagnostic tool for monitoring the level of protein C in plasma. Here, we present a fusion protein where thrombin and the EGF456 domain of thrombomodulin are connected through a peptide linker. The fusion protein recapitulates the functional and structural properties of the thrombin-thrombomodulin complex, prolongs the clotting time by generating pharmacological quantities of activated protein C and effectively diagnoses protein C deficiency in human plasma. Notably, these functions do not require exogenous thrombomodulin, unlike other anticoagulant thrombin derivatives engineered to date. These features make the fusion protein an innovative step toward the development of protein C activators of clinical and diagnostic relevance.

Indexed as

Endothelial Protein C ReceptorHumansPeptidesProtein CProtein C DeficiencyRecombinant Fusion ProteinsThrombomodulinEndothelial Protein C ReceptorPeptidesProtein CRecombinant Fusion ProteinsThrombomodulin

Identifiers

PMID28294177
PMCPMC5353707
OpenAlexW2683175618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.